

BIODELIVERY SCIENCES INTERNATIONAL INC
Form SC 13G/A
February 17, 2015

SCHEDULE 13G

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

BioDelivery Sciences International, Inc.
(Name of Issuer)

Common Stock, par value \$0.001 per share
(Title of Class of Securities)

09060J106
(CUSIP Number)

December 31, 2014
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

***The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.**

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 10 Pages

CUSIP No. 09060J106

**NAMES OF
REPORTING PERSONS
I.R.S. IDENTIFICATION
NOS. OF ABOVE
PERSONS (entities only)**

1

Baker Bros. Advisors LP

13-4093645

**CHECK
THE
APPROPRIATE
BOX IF A (a) "
MEMBER
2 OF A (b) "
GROUP
(See
Instructions)**

2

SEC USE ONLY

3

**CITIZENSHIP OR
PLACE OF
ORGANIZATION**

4

Delaware

**SOLE
VOTING
POWER**

5

**NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH**

2,349,021
**6 SHARED
VOTING
POWER**

-0-
**SOLE
DISPOSITIVE
POWER**

7

2,349,021
**SHARED
DISPOSITIVE
POWER**

8

-0-
**AGGREGATE AMOUNT
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON**

9

2,349,021
**CHECK
BOX IF
THE
AGGREGATE
AMOUNT
IN ROW (9)
EXCLUDES**
CERTAIN
SHARES
(See
Instructions)**

10

**PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW 9**

11

4.4% (1)
**TYPE OF REPORTING
PERSON (See
Instructions)**

12

IA, PN

(1) Based on 51,301,429 shares of common stock outstanding as of November 3, 2014 reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2014.

Page 2 of 10 Pages

CUSIP No. 09060J106

**NAMES OF
REPORTING PERSONS
I.R.S. IDENTIFICATION
NOS. OF ABOVE
PERSONS (entities only)**

1

Baker Bros. Advisors (GP)
LLC

46-3147749

**CHECK
THE
APPROPRIATE
BOX IF A (a) "
MEMBER
2 OF A (b) "
GROUP
(See
Instructions)**

2

SEC USE ONLY

3

**CITIZENSHIP OR
PLACE OF
4 ORGANIZATION**

4

Delaware

**SOLE
VOTING
POWER**

5

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON

2,349,021
6 SHARED
VOTING

POWER

-0-

**SOLE
DISPOSITIVE
POWER**

7

2,349,021

**SHARED
DISPOSITIVE
POWER**

8

-0-

**AGGREGATE AMOUNT
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON**

9

2,349,021

**CHECK
BOX IF
THE
AGGREGATE
AMOUNT
IN ROW (9)
EXCLUDES**
CERTAIN
SHARES**

10

**(See
Instructions)**

**PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW 9**

11

4.4% (1)

12

**TYPE OF REPORTING
PERSON (See
Instructions)**

HC, OO

(1) Based on 51,301,429 shares of common stock outstanding as of November 3, 2014 reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2014.

Page 3 of 10 Pages

CUSIP No. 090601106

1 NAMES OF
REPORTING PERSONS
I.R.S. IDENTIFICATION
NOS. OF ABOVE
PERSONS (entities only)

Felix J. Baker
2 CHECK
THE
APPROPRIATE
BOX IF A (a) "
MEMBER
OF A (b) "
GROUP
(See
Instructions)

3 SEC USE ONLY

4 CITIZENSHIP OR
PLACE OF
ORGANIZATION

United States
5 SOLE
VOTING
POWER

6 2,349,021
SHARED
VOTING
POWER
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
-0-

**SOLE
DISPOSITIVE
POWER**

7

2,349,021
**SHARED
DISPOSITIVE
POWER**

8

-0-

**AGGREGATE AMOUNT
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON**

9

2,349,021
**CHECK
BOX IF
THE
AGGREGATE
AMOUNT
IN ROW (9)
EXCLUDES**
CERTAIN
SHARES
(See
Instructions)**

10

**PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW 9**

11

4.4% (1)
**TYPE OF REPORTING
PERSON (See
Instructions)**

12

IN, HC

(1)

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G/A

Based on 51,301,429 shares of common stock outstanding as of November 3, 2014 reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2014.

Page 4 of 10 Pages

CUSIP No. 090601106

1 NAMES OF
REPORTING PERSONS
I.R.S. IDENTIFICATION
NOS. OF ABOVE
PERSONS (entities only)

Julian C. Baker
2 CHECK
THE
APPROPRIATE
BOX IF A (a) "
MEMBER
OF A (b) "
GROUP
(See
Instructions)

3 SEC USE ONLY

4 CITIZENSHIP OR
PLACE OF
ORGANIZATION

United States
SOLE
VOTING
POWER
5

2,349,021
SHARED
VOTING
POWER
6 NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
-0-

**SOLE
DISPOSITIVE
POWER**

7

2,349,021
**SHARED
DISPOSITIVE
POWER**

8

-0-

**AGGREGATE AMOUNT
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON**

9

2,349,021
**CHECK
BOX IF
THE
AGGREGATE
AMOUNT
IN ROW (9)
EXCLUDES**
CERTAIN
SHARES
(See
Instructions)**

10

**PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW 9**

11

4.4% (1)
**TYPE OF REPORTING
PERSON (See
Instructions)**

12

IN, HC

(1)

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G/A

Based on 51,301,429 shares of common stock outstanding as of November 3, 2014 reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2014.

Page 5 of 10 Pages

Amendment No. 4 to Schedule 13G

This Amendment No. 4 to Schedule 13G amends and supplements the previously filed Schedules 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker. Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

Item 1(a) Name of Issuer:

BioDelivery Sciences International, Inc. (the “Issuer”)

Item 1(b) Address of Issuer’s Principal Executive Offices:

801 Corporate Center Drive, Ste. 210

Raleigh, NC 27607

Item 2(a) Name of Person Filing:

This Schedule 13G is being filed jointly by the Adviser, Adviser GP, Felix J. Baker and Julian C. Baker (collectively, the “Reporting Persons”).

Item 2(b) Address of Principal Business Office or, if None, Residence:

The business address of each of the Reporting Persons is:

c/o Baker Bros. Advisors LP

667 Madison Avenue, 21st Floor

New York, NY 10065

(212) 339-5690

Item 2(c) Citizenship:

The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

Item 2(d) Title of Class of Securities:

Common Stock, par value \$0.01 per share (“Common Stock”)

Item 2(e) CUSIP Number:

09060J106

Page 6 of 10 Pages

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Exchange Act.
- (b) Bank as defined in section 3(a)(6) of the Exchange Act.
- (c) Insurance company as defined in section 3(a)(19) of the Exchange Act.
- (d) Investment company registered under section 8 of the Investment Company Act of 1940.
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 4 are incorporated herein reference. Set forth below is the aggregate number of shares of Common Stock of the Issuer directly held by each of the Funds (as defined below), which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as shares of Common Stock that may be acquired upon conversion of the Series A Preferred Stock ("Series A Preferred") convertible on a one for one basis into shares of Common Stock of the Issuer, by the Funds (as defined below), subject to the limitation on conversion described below. Such securities are directly held by each of Baker Brothers Life Sciences, L.P. ("Life Sciences"), 14159, L.P. ("14159"), and 667, L.P. ("667", and together with Life Sciences and 14159, the "Funds").

Page 7 of 10 Pages

| Name | Number of Shares of Common Stock we own or have the right to acquire within 60 days | Percent of Class Outstanding | |
|------------------------------------|---|------------------------------------|---|
| 667, L.P. | 184,686 | 0.3 | % |
| Baker Brothers Life Sciences, L.P. | 2,118,490 | 4.0 | % |
| 14159, L.P. | 45,845 | 0.1 | % |
| Total | 2,349,021 | 4.4 | % |

The Series A Preferred is only exercisable to the extent that the holders thereof together with their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 9.98% of the outstanding shares of Common Stock of the Issuer after exercise. As a result of this restriction, the number of shares that may be issued upon conversion of the Series A Preferred by the above holders may change depending upon changes in the outstanding shares. The number of shares of Common Stock issuable upon conversion of the Series A Preferred held by any Reporting Person affiliate will also depend upon the extent to which the Series A Preferred held by other affiliates have theretofore been converted.

Pursuant to the amended and restated management agreements among the Adviser, the Funds and their respective general partners, the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments.

The Adviser GP, Felix J. Baker and Julian C. Baker as principals of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities held by each of the Funds, and this Amendment No. 4 shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Page 8 of 10 Pages

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

The information in Item 4 is incorporated herein by reference.

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 17, 2015

**BAKER BROS.
ADVISORS LP**

By: Baker Bros. Advisors
(GP) LLC, its general
partner

By: /s/ Scott L. Lessing
Name: Scott L. Lessing
Title: President

**BAKER BROS.
ADVISORS (GP) LLC**

By: /s/ Scott L. Lessing
Name: Scott L. Lessing
Title: President

/s/ Julian C. Baker
Julian C. Baker

/s/ Felix J. Baker
Felix J. Baker

Page 10 of 10 Pages